MedTrace Logo

Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

NCT01652599 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-01-07

No results posted yet for this study

Summary

The purpose of this study is to determine the response rate and response duration with the combination of eltrombopag and high-dose dexamethasone

Conditions

  • Immune Thrombocytopenic Purpura

Interventions

DRUG

Eltrombopag and dexamethasone

Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4

Sponsors & Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Principal Investigators

  • David Gomez-Almaguer, MD · Hospital Universitario Dr. Jose E. Gonzalez

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-06-30
Completion
2013-11-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01652599 on ClinicalTrials.gov